🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data

Recruitingn/aAges 18 Years - anyAllAbbVie
NCT07419347 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Prescribed 8 weeks of Glecaprevir/Pibrentasvir (G/P). * Treatment-naïve (for the current infection, participants that may have had prior infections which were resolved with treatment are considered naive for current infection as long as they have not received any treatment for the current infection.) * Is concomitantly on one or more prescription medications or illicit drugs. Exclusion Criteria: * Treated with DAAs other than G/P. * History of decompensated cirrhosis. * Had Hepatitis-B virus (HBV) infection. * Had hepatocellular carcinoma (HCC).
💊

What it tests

  • Not listed
📍

Where

2 sites
Vancouver Infectious Diseases Centre /ID# 275313
Vancouver, Canada
St. Clair Medical Clinic /ID# 275334
Toronto, Canada
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy